In a single-arm, dose-escalation Phase I trial (NCT05240950), anti-CEA CAR T-cells were administered to patients with colorectal cancer liver metastases (CRLM) who had no evidence of disease post-treatment and ≥ 30% CEA expression. Here, CEACAM5 is linked to colorectal cancer.